Astria Therapeutics (NASDAQ:ATXS) Earns “Buy” Rating from HC Wainwright

Astria Therapeutics (NASDAQ:ATXS)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research note issued to investors on Thursday,Benzinga reports. They currently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 50.52% from the stock’s current price.

A number of other analysts have also issued reports on ATXS. Oppenheimer boosted their price target on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research note on Thursday. TD Cowen initiated coverage on shares of Astria Therapeutics in a report on Monday, July 29th. They set a “buy” rating and a $35.00 target price on the stock. Wedbush restated an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Finally, Evercore ISI upgraded Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Price Performance

Shares of ATXS stock traded up $0.02 during trading hours on Thursday, hitting $10.63. The company had a trading volume of 126,032 shares, compared to its average volume of 614,761. The stock has a market capitalization of $599.80 million, a PE ratio of -4.53 and a beta of 0.71. The company’s fifty day moving average is $11.46 and its 200 day moving average is $10.61. Astria Therapeutics has a fifty-two week low of $4.26 and a fifty-two week high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.05). Equities analysts forecast that Astria Therapeutics will post -1.68 earnings per share for the current year.

Hedge Funds Weigh In On Astria Therapeutics

Several large investors have recently bought and sold shares of the business. Quest Partners LLC boosted its position in shares of Astria Therapeutics by 3,310.6% during the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 2,861 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Astria Therapeutics during the 3rd quarter worth approximately $155,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Astria Therapeutics in the 1st quarter valued at $200,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Astria Therapeutics in the 2nd quarter valued at $171,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.